Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-457 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1 Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-457 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HZN-457 (Primary)
  • Indications Gout
  • Focus Adverse reactions; First in man
  • Sponsors Horizon Therapeutics plc

Most Recent Events

  • 06 Sep 2023 Status changed from active, no longer recruiting to completed.
  • 16 Jun 2023 Status changed from recruiting to active, no longer recruiting.
  • 06 Feb 2023 According to an Arrowhead Pharmaceuticals media release, the company earned a $15 million milestone payment from Horizon Therapeutics after the first subject was enrolled.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top